| Date | Title | Description |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding.
The round was led by New Leaf Ve... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing.
The round was co-led by RA Capital Management, Fidelity Ma... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| 27.10.2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| 09.09.2024 | Стартап в сфере клеточной терапии ArsenalBio привлек $325 млн | В раунде финансирования Arsenal Biosciences приняли участие новые инвесторы ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (венчурное подразделение NVIDIA), Luma Group, фонды, консультируемые T. Rowe Price... |
| 04.09.2024 | ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs | Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round.
This fund... |
| 04.09.2024 | ArsenalBio Raises $325M in Series C Funding | ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding.
The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, fu... |
| 13.08.2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |
| 28.07.2024 | The Resurgence of Private Equity and Health Tech Investments | The world of finance is like a tide. It ebbs and flows, sometimes revealing treasures, sometimes hiding them. Recently, the tide has turned, bringing a wave of activity in private equity and health technology investments. The recent acquisi... |
| 28.07.2024 | The Race for Healthcare Investment: A New Era in Medical Capital | The healthcare landscape is shifting. Private equity firms are circling like hawks, eyeing lucrative investments in medical institutions. The Asian Institute of Medical Sciences (AIMS) in Faridabad is the latest prize. With a valuation of ₹... |
| 26.07.2024 | Imperative Care closes potential $150M Series E and more digital health fundings | Photo: Anchiy/Getty Images
Medical technology company Imperative Care announced it initially closed an oversubscribed Series E financing round led by Ally Bridge Group. The company says additional closings of the round could bring its Serie... |
| 11.06.2024 | Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth | Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform
NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody, the leading national... |
| 26.10.2021 | Patina Emerges Out of Stealth with $50M to Reinvent Primary Care & Aging Experience | What You Should Know:
– Patina Health Inc. (PatinaTM) came out of stealth today to announced its $57M Series A round from healthcare investors Andreessen Horowitz (a16z) and GV (formerly Google Ventures), who co-led the Seed and Series A ro... |
| 17.06.2021 | UCL, Imperial College London and University of Cambridge are behind innovative industry university collaboration receiving £100m funding to rapidly advance cutting-edge science | |
| 18.03.2019 | Rock Springs Capital Leads $63M Series B For Imara | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, today announced the closing of an oversubscribed $63 million Series B cross-over fi... |
| 18.07.2017 | Rock Springs Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 18.07.2017 | F-Prime Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 24.11.2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 09.09.2015 | Daily funding roundup - September 9, 2015 | Didi Kuaidi scored $1B; Chef bagged $40M; Primus Power raised $25M
The battle for supremacy among e-hailing services in China is heating up, and fast. In the same week that Uber revealed that it has raised an additional $1.2 billion to expa... |
| 24.07.2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M
AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing |
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo... |